By Dean Seal
Inogen said regulators have cleared its SIMEOX 200 Airway Clearance Device to be used by U.S. patients with chronic respiratory diseases.
The medical technology company said Monday that the Food and Drug Administration's 510(k) clearance paves the way for a limited launch of SIMEOX 200 in targeted sites next year.
The device promotes bronchial drainage and is intended for patients with chronic lung diseases associated with mucus hypersecretion and mucus retention, including chronic obstructive pulmonary diseases, or COPD, and cystic fibrosis.
Chief Executive Kevin Smith said the company intends to bring the device to patients within the next year.
Shares rose 3.6% to $8.89 in premarket trading.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 30, 2024 08:49 ET (13:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。